An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis

Xin H, Zhong Y, Zhang M, Wu L, Li Q, Li X, Wu Y, Zhang L, Peng J, Xie C, Zhu D, Hao Y, Guan Y, Wang K

Drug Design, Development and Therapy 2026, 20:598742

Published Date: 18 May 2026